Projet transMed (Horizon 2020, appel à projets 2017)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Medicine today experiences a gap between basic research and successful clinical translation that delays establishment of urgently needed therapies. This is very clearly so in blinding retinal degenerations (RDs), where most are yet untreatable, even with a wealth of basic and pre-clinical research data available. To address this problem, transMed proposes an innovative programme to educate “translational researchers” that focuses on the bench-to-bedside development of treatments for RD. The transMed consortium joins four academic groups (EKUT, UNIMORE, ULUND, HI) with four non-academic and SME partners (SPPD, INCU, Oculis, PamGene), and five partner organisations (2BBB, BIOLOG, NLO, HCTC, EVI) with intersectoral collaborations already ongoing. Each transMed partner will contribute specific critical expertise to a curriculum covering all major aspects of translational research: From basic research into disease mechanisms and target definition, to drug design and development, in vitro test systems and in vivo disease models, drug delivery systems, biomarkers, good manufacturing practice, toxicological testing and pharmacokinetics, regulatory affairs, intellectual property, all the way to clinical trials and commercialisation. transMed builds on and integrates three relevant translational projects, which are at the early pre-clinical, late pre-clinical, and early clinical stages, respectively, to provide the project’s Early Stage Researchers with the broadest possible overview. The training is completed by e-lectures, the inclusion of dedicated conferences for young researchers, a secondment and hands-on course programme from industry to academia and vice versa, permitting further insight and networking in the European biotech industry. Altogether, transMed will offer its students the opportunity to obtain a competitive PhD degree in several critical areas of biomedical research, providing for a strong employability in both the private and public sector.

Mots clés : drug delivery systems, cgmp signalling, retinitis pigmentosa, retina, vision, translational, research, blood retinal barrier, blood brain barrier

Participants :
- Hannover Medical School (Allemagne) — Partner, organization partner, Recherche, subvention : 0.0 €
- Oculis ehf (Islande) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- Sp process development ab (Suède) — Partner, beneficiary, Recherche, subvention : 0.0 €
- Pamgene international bv (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 255374.28 €
- European vision institute - eeig (Belgique) — Partner, organization partner, Recherche, subvention : 0.0 €
- RISE Research Institutes of Sweden (Suède) — Partner, beneficiary, Recherche, subvention : 527318.64 €
- Nlo european patent and trademark (Pays-Bas) — Partner, organization partner, Autres, subvention : 0.0 €
- University of Iceland (Islande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 538290.72 €
- University of Tübingen (Allemagne) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 498432.96 €
- University of Modena and Reggio Emilia (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 516122.64 €
- Biolog Life Science Institute (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Lund University (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 527318.64 €
- Inocure sro (Rép. Tchèque) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 464844.96 €
- 2-bbb medicines bv (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €